静注用リポプロスタグランデイン（PG）E<sub>1</sub>製剤の比較

DOI Web Site Web Site 被引用文献2件 参考文献47件

書誌事項

タイトル別名
  • The Comparison Study of Lipo PGE<sub>1</sub> Preparations
  • 静注用リポプロスタグランデイン(PG)E1製剤の比較
  • ジョウチュウヨウ リポ プロスタグランデイン PG E1 セイザイ ノ ヒカク

この論文をさがす

抄録

  The comparison study was performed with 3 kinds of Lipo PGE1 (5 μg/ml) preparations (Formulation A, B, and C), which are now used in clinical. Under alkali condition, Lipo PGE1 (5 μg/ml) preparations in combination with physiological solution containing calcium ion were susceptible to stop dropping because of the formation of aggregates. There was a difference of feasibility to form aggregates among these preparations. The percentage of PGE1 in the LM (lipid microspheres) was 68.8% (Formulation A) when determined by filtration with the pore size of 0.1 μm, and the respective value (%) of Formulation B and Formulation C was 43.0% and 13.9%. This indicates that the latter formulations were significantly susceptible to leak from the LM. PGE1 can induce an extensive irritation. The potency of irritation was the most in Formulation C. This seems similar with the result of LM retention of PGE1. PGE1 increased the blood flow. Formulation A reached the peak by 2.27 fold, which was significantly higher than Formulation C and PGE1 alone (PGE1-cyclodextrin, PGE1-CD). The peak was also significantly higher in Formulation B than that of PGE1-CD. The AUC value of blood flow rate showed a significant increase in Formulation A and Formulation B as compared to that of PGE1-CD. Drug retention in the LM can be a determinant factor for drug distribution and pharmacological effect. This study indicates that there can be some differences among Lipo PGE1 preparations, which have the same drug dose.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 127 (8), 1237-1243, 2007-08-01

    公益社団法人 日本薬学会

被引用文献 (2)*注記

もっと見る

参考文献 (47)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ